ACT DMD Update with PTC (February 2014)
On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD).
February 12, 2014 /
by: Parent Project Muscular Dystrophy
